2169 related articles for article (PubMed ID: 25926352)
1. Phase II Trial of Preoperative Radiation With Concurrent Capecitabine, Oxaliplatin, and Bevacizumab Followed by Surgery and Postoperative 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX), and Bevacizumab in Patients With Locally Advanced Rectal Cancer: 5-Year Clinical Outcomes ECOG-ACRIN Cancer Research Group E3204.
Landry JC; Feng Y; Prabhu RS; Cohen SJ; Staley CA; Whittington R; Sigurdson ER; Nimeiri H; Verma U; Benson AB
Oncologist; 2015 Jun; 20(6):615-6. PubMed ID: 25926352
[TBL] [Abstract][Full Text] [Related]
2. Phase 2 study of preoperative radiation with concurrent capecitabine, oxaliplatin, and bevacizumab followed by surgery and postoperative 5-fluorouracil, leucovorin, oxaliplatin (FOLFOX), and bevacizumab in patients with locally advanced rectal cancer: ECOG 3204.
Landry JC; Feng Y; Cohen SJ; Staley CA; Whittington R; Sigurdson ER; Nimeiri H; Verma U; Prabhu RS; Benson AB
Cancer; 2013 Apr; 119(8):1521-7. PubMed ID: 23288663
[TBL] [Abstract][Full Text] [Related]
3. Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial.
Hong YS; Nam BH; Kim KP; Kim JE; Park SJ; Park YS; Park JO; Kim SY; Kim TY; Kim JH; Ahn JB; Lim SB; Yu CS; Kim JC; Yun SH; Kim JH; Park JH; Park HC; Jung KH; Kim TW
Lancet Oncol; 2014 Oct; 15(11):1245-53. PubMed ID: 25201358
[TBL] [Abstract][Full Text] [Related]
4. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Rödel C; Graeven U; Fietkau R; Hohenberger W; Hothorn T; Arnold D; Hofheinz RD; Ghadimi M; Wolff HA; Lang-Welzenbach M; Raab HR; Wittekind C; Ströbel P; Staib L; Wilhelm M; Grabenbauer GG; Hoffmanns H; Lindemann F; Schlenska-Lange A; Folprecht G; Sauer R; Liersch T;
Lancet Oncol; 2015 Aug; 16(8):979-89. PubMed ID: 26189067
[TBL] [Abstract][Full Text] [Related]
5. Efficacy endpoints of radiation therapy group protocol 0247: a randomized, phase 2 study of neoadjuvant radiation therapy plus concurrent capecitabine and irinotecan or capecitabine and oxaliplatin for patients with locally advanced rectal cancer.
Wong SJ; Moughan J; Meropol NJ; Anne PR; Kachnic LA; Rashid A; Watson JC; Mitchell EP; Pollock J; Lee RJ; Haddock M; Erickson BA; Willett CG
Int J Radiat Oncol Biol Phys; 2015 Jan; 91(1):116-23. PubMed ID: 25446610
[TBL] [Abstract][Full Text] [Related]
6. Pathological response and safety of two neoadjuvant strategies with bevacizumab in MRI-defined locally advanced T3 resectable rectal cancer: a randomized, noncomparative phase II study.
Borg C; André T; Mantion G; Boudghène F; Mornex F; Maingon P; Adenis A; Azria D; Piutti M; Morsli O; Bosset JF
Ann Oncol; 2014 Nov; 25(11):2205-2210. PubMed ID: 25122693
[TBL] [Abstract][Full Text] [Related]
7. Radiation Therapy Oncology Group 0247: a randomized Phase II study of neoadjuvant capecitabine and irinotecan or capecitabine and oxaliplatin with concurrent radiotherapy for patients with locally advanced rectal cancer.
Wong SJ; Winter K; Meropol NJ; Anne PR; Kachnic L; Rashid A; Watson JC; Mitchell E; Pollock J; Lee RJ; Haddock M; Erickson BA; Willett CG
Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):1367-75. PubMed ID: 21775070
[TBL] [Abstract][Full Text] [Related]
8. Intergroup Randomized Phase III Study of Postoperative Oxaliplatin, 5-Fluorouracil, and Leucovorin Versus Oxaliplatin, 5-Fluorouracil, Leucovorin, and Bevacizumab for Patients with Stage II or III Rectal Cancer Receiving Preoperative Chemoradiation: A Trial of the ECOG-ACRIN Research Group (E5204).
Chakravarthy AB; Zhao F; Meropol NJ; Flynn PJ; Wagner LI; Sloan J; Diasio RB; Mitchell EP; Catalano P; Giantonio BJ; Catalano RB; Haller DG; Awan RA; Mulcahy MF; O'Brien TE; Santala R; Cripps C; Weis JR; Atkins JN; Leichman CG; Petrelli NJ; Sinicrope FA; Brierley JD; Tepper JE; O'Dwyer PJ; Sigurdson ER; Hamilton SR; Cella D; Benson AB
Oncologist; 2020 May; 25(5):e798-e807. PubMed ID: 31852811
[TBL] [Abstract][Full Text] [Related]
9. Evolving role of neoadjuvant therapy in rectal cancer.
Schrag D
Curr Treat Options Oncol; 2013 Sep; 14(3):350-64. PubMed ID: 23828092
[TBL] [Abstract][Full Text] [Related]
10. Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial.
de Gramont A; Van Cutsem E; Schmoll HJ; Tabernero J; Clarke S; Moore MJ; Cunningham D; Cartwright TH; Hecht JR; Rivera F; Im SA; Bodoky G; Salazar R; Maindrault-Goebel F; Shacham-Shmueli E; Bajetta E; Makrutzki M; Shang A; André T; Hoff PM
Lancet Oncol; 2012 Dec; 13(12):1225-33. PubMed ID: 23168362
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Two Neoadjuvant Strategies With Bevacizumab in MRI-Defined Locally Advanced T3 Resectable Rectal Cancer: Final Results of a Randomized, Noncomparative Phase 2 INOVA Study.
Borg C; Mantion G; Boudghène F; Mornex F; Ghiringhelli F; Adenis A; Azria D; Balosso J; Ben Abdelghani M; Bachet JB; Vendrely V; François Y; Conroy T; Rio E; Roullet B; Spaëth D; Quero L; Lakkis Z; Coudert M; Ionescu-Goga M; Tanang A; André T
Clin Colorectal Cancer; 2019 Sep; 18(3):200-208.e1. PubMed ID: 31311761
[TBL] [Abstract][Full Text] [Related]
12. Assessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer: A Subgroup Analysis of the TOSCA Randomized Clinical Trial.
Petrelli F; Labianca R; Zaniboni A; Lonardi S; Galli F; Rulli E; Rosati G; Corallo S; Ronzoni M; Cardellino GG; Mattioli R; Mambrini A; Ciuffreda L; Banzi M; Pusceddu V; Maiello E; Zampino M; Zagonel V; Marchetti P; Corsi D; Rimassa L; Cinieri S; Sobrero A
JAMA Oncol; 2020 Apr; 6(4):547-551. PubMed ID: 32053133
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: a pilot trial.
Schrag D; Weiser MR; Goodman KA; Gonen M; Hollywood E; Cercek A; Reidy-Lagunes DL; Gollub MJ; Shia J; Guillem JG; Temple LK; Paty PB; Saltz LB
J Clin Oncol; 2014 Feb; 32(6):513-8. PubMed ID: 24419115
[TBL] [Abstract][Full Text] [Related]
14. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M;
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206
[TBL] [Abstract][Full Text] [Related]
15. Feasibility of Neoadjuvant FOLFOX Therapy Without Radiotherapy for Baseline Resectable Rectal Cancer.
Koizumi M; Yamada T; Shinji S; Yokoyama Y; Takahashi G; Iwai T; Takeda K; Hara K; Ohta K; Uchida E; Yoshida H
In Vivo; 2018; 32(4):937-943. PubMed ID: 29936483
[TBL] [Abstract][Full Text] [Related]
16. Phase II Trial of Neoadjuvant Chemotherapy, Chemoradiotherapy, and Laparoscopic Surgery with Selective Lateral Node Dissection for Poor-Risk Low Rectal Cancer.
Konishi T; Shinozaki E; Murofushi K; Taguchi S; Fukunaga Y; Nagayama S; Fujimoto Y; Akiyoshi T; Nagasaki T; Suenaga M; Chino A; Kawachi H; Yamamoto N; Ishikawa Y; Oguchi M; Ishizuka N; Ueno M; Yamaguchi K
Ann Surg Oncol; 2019 Aug; 26(8):2507-2513. PubMed ID: 30963400
[TBL] [Abstract][Full Text] [Related]
17. A phase I/II study of oxaliplatin when added to 5-fluorouracil and leucovorin and pelvic radiation in locally advanced rectal cancer: a Colorectal Clinical Oncology Group (CCOG) study.
Sebag-Montefiore D; Glynne-Jones R; Falk S; Meadows HM; Maughan T
Br J Cancer; 2005 Oct; 93(9):993-8. PubMed ID: 16249791
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant bevacizumab, oxaliplatin, 5-fluorouracil, and radiation for rectal cancer.
Dipetrillo T; Pricolo V; Lagares-Garcia J; Vrees M; Klipfel A; Cataldo T; Sikov W; McNulty B; Shipley J; Anderson E; Khurshid H; Oconnor B; Oldenburg NB; Radie-Keane K; Husain S; Safran H
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):124-9. PubMed ID: 20947267
[TBL] [Abstract][Full Text] [Related]
19. Phase I/II study of preoperative oxaliplatin, fluorouracil, and external-beam radiation therapy in patients with locally advanced rectal cancer: Cancer and Leukemia Group B 89901.
; Ryan DP; Niedzwiecki D; Hollis D; Mediema BE; Wadler S; Tepper JE; Goldberg RM; Mayer RJ
J Clin Oncol; 2006 Jun; 24(16):2557-62. PubMed ID: 16636336
[TBL] [Abstract][Full Text] [Related]
20. Risk-adapted adjuvant chemotherapy after concomitant fluoropyrimidine-radiotherapy neoadjuvant treatment for patients with resectable cT3-4 or N+ rectal cancer.
Sastre J; Custodio A; Sanchez JC; Ortega L; Rodriguez L; Puente J; Corona J; Alfonso R; de las Heras M; Dıaz-Rubio E
Anticancer Drugs; 2011 Feb; 22(2):185-90. PubMed ID: 21218606
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
